Ciara Louise Freeman

Assistant Professor

H Lee Moffitt Cancer Center and Research Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Purpose: Sarcopenia is a hallmark of cancer cachexia. Chimeric antigen receptor (CAR) T-cell therapy is associated with an inflammatory state that may exacerbate sarcopenia. The relationship among CAR T-cell therapy, sarcopenia, and metabolism is poorly understood. Experimental Design: In 83 patients with large B-cell lymphoma, the skeletal muscle index was measured from clinical images obtained at baseline and days 30 and 90 after therapy. Serum metabolomics ( n = 57 patients) was performed in the first 4 weeks. Results: Baseline sarcopenia was present in more than half of patients and associated with shorter median overall survival than for non-sarcopenic patients (10.5 vs. 34.3 months; P = 0.006). This reduction was due to increased nonrelapse mortality with all six nonrelapse mortality events occurring in patients with baseline sarcopenia. In the first 30 days after CAR T-cell therapy, one of three patients experienced skeletal muscle loss greater than 10%. Muscle loss was associated with higher tumor burden and neurotoxicity but was not significantly associated with long-term survival. Serum metabolomics revealed an early (weeks 1–2) increase in purine metabolites, followed by a later (weeks 3–4) increase in triglyceride levels. The serum metabolite with the highest fold-increase from baseline was adipic acid, attributed to the inpatient hospital menu of jello and other tart beverages. Conclusions: Skeletal muscle loss after CAR T-cell therapy is common and is associated with fatty acid catabolism. Patients with baseline sarcopenia have poor tolerance and reduced survival. Future studies of dietary and exercise interventions may improve CAR T-cell therapy outcomes.

Year:

2025

Chimeric antigen receptor T-cells targeting BCMA have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM) with two approved products, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). To explore biological differences, we analyzed pre-infusion products (IP) and CAR-enriched peripheral blood mononuclear cells (PBMCs) at expansion using single-cell RNA sequencing (scRNAseq) from 52 samples. Post-quality control 247,500 cells (117,530 CD4, 80,939 CD8) were analyzed. We found that ide-cel IPs from durable responders (DR) had higher construct expression, enhanced NFKB signaling, and anti-apoptotic signatures, correlating with improved progression free survival. CAR + ide-cel PBMCs in DRs showed upregulated ribosomal genes and higher CD27, KLF2, TCF7 expression. Relative to ide-cel, cilta-cel CAR + cells showed higher expression of CD27, GZMK, TCF7, and a 4-fold increase in CAR expression. In addition, the TCR repertoire was less clonal and more diverse. This study elucidates the distinct characteristics of ide-cel and cilta-cel, offering insights into their differing clinical efficacy.

Year:

2024

Collaborators (14)

Johannes Fahrmann

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marco Davila

SVP, Translational Research

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Julio Chavez

Associate Professor

Moffitt Cancer Center

UNITED STATES
View details

Christina Bachmeier

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Samir M. Hanash

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marion Subklewe

Head of Hematology with Focus on Cellular Therapy, CAR T and ECTU & LMU - Gene Center - Head of the Laboratory of Translational Cancer Immunology

Ludwig-Maximilians-Universität München

GERMANY
View details

Omar Castaneda Puglianini

Associate Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Aditi Saha

Assistant Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Jay Spiegel

Assistant Professor

University of Miami

UNITED STATES
View details

Robert Jenq

Professor

City Of Hope National Medical Center

UNITED STATES
View details

Michael Jain

Associate Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Neeraj Y Saini

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marion Subklewe

LMU University Hospital

GERMANY
View details

Fabiana Perna

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details